drugset / Trial / NCT00667719

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

NCT00667719

Phase 3 Completed 564 enrolled Novartis
NaSingle-groupOpen-labelTreatment

Summary

This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.

Timeline

Start
2008-06-05
Primary completion
2009-10-05
Completion
2009-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg Oral
Subject Amlodipine Other / unclassified 10 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral